Quidel Corp
Abrir
12.16 -3.26
Visão Geral
Variação de preço das ações
24h
Mín
11.9
Máximo
13.01
Rendimento | -1.1M -93M |
|---|---|
Vendas | 11M 631M |
Margem de lucro | -14.725 |
Funcionários | 6,500 |
Recomendações | Vender |
|---|---|
Previsão para 12 meses | +18.67% upside |
Próximos Ganhos | 4 de nov. de 2026 |
|---|
Capitalização de Mercado | 78M 796M |
|---|---|
Abertura anterior | 15.42 |
Fecho anterior | 12.16 |
Quidel Corp Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Notícias Relacionadas
Comparação entre Pares
Variação de preço
Quidel Corp Previsão
Preço-alvo
By TipRanks
18.67% parte superior
Previsão para 12 meses
Média 15 USD 18.67%
Máximo 18 USD
Mínimo 12 USD
Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Quidel Corp - Dist nos últimos 3 meses.
Informação Financeira
Custos administrativos e de venda
Lucro antes de imposto
Vendas
Custo das vendas
Lucro bruto sobre vendas
Despesa com juros da dívida
Resultado Operacional
$
Sobre Quidel Corp
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
